Published on November 19, 2012 at 3:53 AM
GVK Biosciences (GVK BIO), Asia's leading Drug Discovery Research & Development organization, has received approvals from the Atomic Energy Regulatory Board (AERB), Government of India, to carry out 3H and 14C synthesis activities. This GLP compliant facility has state-of-the-art equipment to cater to the requirements of companies engaged in the fields of Drug Discovery and Development, Agro and Veterinary Chemicals, Cosmetics, Perfumery and Specialty Studies.
Speaking of this development, Manni Kantipudi, CEO, GVK BIO, said, "Several of our customers requested us to extend our chemistry services to include isotope labeling services. We listened to our customers and setup this state-of-the art facility which is the largest such facility in India. The facility has received all statutory approvals from the Atomic Energy Review Board of India."
Source: GVK Biosciences